About 209,000 results
Any time 
Open links in new tab
Lilly weight-loss drug copycats dealt blow
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
- People also ask
What end of Eli Lilly's weight-loss drug shortage means for the …
WEB1 day ago · The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses ...
- bing.com/videosWatch full video
Drugmaker Lilly slates another $4.5B for manufacturing …
WEB3 days ago · Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve manufacturing. The company said in May that it also was expanding there to make more …
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
WEB2 days ago · “The entities currently mass-producing and mass-marketing compounded and counterfeit tirzepatide need to stop immediately,” Eli Lilly, the maker of Zepbound and Mounjaro, said in an emailed ...
Tirzepatide cuts risk of diabetes by 94% in adults with ... - CNN
WEBAug 20, 2024 · A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight...
- Estimated Reading Time: 2 mins
News Release - Eli Lilly and Company
WEBMay 14, 2024 · Lilly has discovered products claiming to be compounded tirzepatide medicines that contain bacteria, high impurity levels, different chemical structures, and different colors than Mounjaro ® or Zepbound ®. In at least one instance, the product …
News Release - Eli Lilly and Company
WEBMay 13, 2022 · Mounjaro is a once-weekly GIP and GLP-1 receptor agonist that improves glycemic control and reduces weight. It is the first new class of diabetes medicines in nearly a decade and will be available in the U.S. in the coming weeks.
News Release - Eli Lilly and Company
WEBJun 20, 2024 · Lilly does not promote or encourage use of Mounjaro ®, Zepbound ®, or any Lilly medicine outside of its FDA-approved indication. Mounjaro ® is an injectable prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit ...
WEBApr 30, 2024 · Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s …
News Release - Eli Lilly and Company
WEBSep 19, 2023 · Because of this, Lilly filed lawsuits to protect patient safety and stop the unlawful marketing and sale of non-FDA approved compounded products fraudulently claiming to be Mounjaro® (tirzepatide) by medical spas, wellness centers and compounding pharmacies.
Lilly hits record high after Mounjaro fuels forecast …
WEBAug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
